Ultima-Tirzepatide

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE GIP/GLP-1 RA ,

Introducing Tirzepatide, a groundbreaking synthetic peptide designed to effectively lower blood sugar levels. This innovative treatment stimulates insulin secretion during both the initial and subsequent phases, while simultaneously reducing glucagon levels in response to glucose fluctuations.

Not only does tirzepatide slow gastric emptying, but it also helps decrease fasting and post-meal glucose levels, curtail appetite, and facilitate weight loss for individuals managing type 2 diabetes. Plus, it enhances insulin sensitivity, making it a comprehensive solution for blood sugar control.

The unique formulation of tirzepatide includes a C20 fatty diacid linked via a hydrophilic connector at lysine position 20. This design allows for robust binding to albumin in the bloodstream, significantly extending its active half-life.

GLP-1 (glucagon-like peptide-1) receptors (GLP-1R) are found throughout the body, including in pancreatic beta-cells and the gastrointestinal tract, playing a vital role in the pathophysiology of type 2 diabetes. GLP-1R signaling is essential for blood sugar regulation, as it enhances insulin secretion in response to glucose, delays gastric emptying, decreases glucagon release, and promotes weight loss through appetite-suppressing pathways in the brain. Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are crucial peptide hormones that help maintain glucose homeostasis by primarily stimulating insulin release from pancreatic beta-cells, with GIP being the predominant incretin hormone that activates insulin secretion post-meal.

While tirzepatide's exact mechanism remains partially understood, its dual activation of GIP and GLP-1 receptors is believed to significantly influence blood sugar levels and weight management. Research suggests that the combination of GIP with a GLP-1R agonist produces a stronger insulin response and greater suppression of glucagon secretion than using either hormone alone. Tirzepatide exhibits high affinity for both GIP and GLP-1R, demonstrating comparable binding affinity to GIP receptors as native GIP, despite having a GLP-1R affinity that is five times lower than that of native GLP-1. This powerful medication effectively activates GLP-1R signaling to promote glucose-dependent insulin secretion, harnessing the benefits of both GIP receptors (GIPR) and GLP-1R. However, further research is essential to fully understand the impact of GIPR activation on blood sugar control and weight management, as findings from preclinical and clinical studies have shown varying results.